Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy

Abstract

Arthritis, rheumatism, and diabetic retinopathy, conditions accompanied by excessive angiogenesis, may be amenable to treatment with the same drugs proposed for cancer therapy. A promising new concept in tumor treatment is the application of integrin antagonists such as 1 and other low molecular weight compounds with antiangiogenic activity. A number of drugs are currently in preclinical and clinical trials.